Abstract
Primary central nervous system (CNS) tumors account for only 2% of all adult cancers and the annual incidence of primary malignant brain cancer was 7.3 per 100,000 person-years. Malignant gliomas are the most common primary CNS tumors in adults accounting for 78% of all primary malignant CNS tumors. Glial neoplasms represent about 40% of all primary CNS tumors, over three quarters being malignant. The median survival of patients with glioblastoma was 14.6 months after tereatment. Although recent basic and clinical research of malignant gliomas has improved, there is limitation of the outcome of the patients with malignant gliomas. Treatment strategy of tumor resection and radiotherapy for this tumor is still important and a recent advance in the use of concurrent chemo-radiation has improved survival in a large fraction of patients. New approaches using these signal transductional and gene researches are developing and may promise for further survival gains in the near future.
Keywords: Signal transduction, brain tumors, target therapy, gene therapy
Current Signal Transduction Therapy
Title: Current Signal Transduction Therapy for Brain Tumors Review Article
Volume: 5 Issue: 3
Author(s): Hidehiro Oka, Yuzuru Niibe, Satoshi Utsuki, Kazushige Hayakawa and Kiyotaka Fujii
Affiliation:
Keywords: Signal transduction, brain tumors, target therapy, gene therapy
Abstract: Primary central nervous system (CNS) tumors account for only 2% of all adult cancers and the annual incidence of primary malignant brain cancer was 7.3 per 100,000 person-years. Malignant gliomas are the most common primary CNS tumors in adults accounting for 78% of all primary malignant CNS tumors. Glial neoplasms represent about 40% of all primary CNS tumors, over three quarters being malignant. The median survival of patients with glioblastoma was 14.6 months after tereatment. Although recent basic and clinical research of malignant gliomas has improved, there is limitation of the outcome of the patients with malignant gliomas. Treatment strategy of tumor resection and radiotherapy for this tumor is still important and a recent advance in the use of concurrent chemo-radiation has improved survival in a large fraction of patients. New approaches using these signal transductional and gene researches are developing and may promise for further survival gains in the near future.
Export Options
About this article
Cite this article as:
Oka Hidehiro, Niibe Yuzuru, Utsuki Satoshi, Hayakawa Kazushige and Fujii Kiyotaka, Current Signal Transduction Therapy for Brain Tumors Review Article, Current Signal Transduction Therapy 2010; 5 (3) . https://dx.doi.org/10.2174/157436210791920256
DOI https://dx.doi.org/10.2174/157436210791920256 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Cetuximab and Other Epidermal Growth Factor Receptor Monoclonal Antibodies in the Treatment of Advanced Non-Small Cell Lung Cancer
Reviews on Recent Clinical Trials The Role of Aryl Hydrocarbon Receptor-Regulated Cytochrome P450 Enzymes in Glioma
Current Pharmaceutical Design Population-based Study of Risk Polymorphisms Associated with Vascular Disorders and Dementia
Current Genomics A Closer Look at α-Secretase
Current Alzheimer Research Ginsenoside Rb1 Directly Scavenges Hydroxyl Radical and Hypochlorous Acid
Current Pharmaceutical Design Determination of Dysregulated miRNA Expression Levels by qRT-PCR after the Application of Usnic Acid to Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Recent Progress and Related Patents on the Applications of Bone Marrow-Derived Stem/Progenitor Cells in Regenerative Medicine and Cancer Therapies
Recent Patents on Regenerative Medicine Pharmacogenetics and Inflammatory Bowel Disease
Current Pharmacogenomics and Personalized Medicine CDK-associated Cullin 1 Promotes Cell Proliferation and Inhibits Cell Apoptosis in Human Glioblastoma
Current Cancer Drug Targets Approaching Neurological Diseases to Reduce Mobility Limitations in Older Persons
Current Pharmaceutical Design Inhibitors of the Microsomal Prostaglandin E2 Synthase-1 as Alternative to Non Steroidal Anti-Inflammatory Drugs (NSAIDs) – A Critical Review
Current Medicinal Chemistry CB1 Cannabinoid Receptors and their Associated Proteins
Current Medicinal Chemistry Editorial [ The Role of Epidermal Growth Factor Receptor (EGFR) Targeting Drugs in the Treatment of Cancer Guest Editor: Fortunato Ciardiello ]
Current Cancer Therapy Reviews Current State of the Art of New Tubulin Inhibitors in the Clinic
Current Clinical Pharmacology Anti-neoplastic and Calcium modulatory action of Caffeic acid phenethyl ester and Dasatinib in C6 glial cells: A Therapeutic Perspective
CNS & Neurological Disorders - Drug Targets The Peripheral Benzodiazepine Receptor: A Promising Therapeutic Drug Target
Current Medicinal Chemistry Vasotrophic Regulation of Age-Dependent Hypoxic Cerebrovascular Remodeling
Current Vascular Pharmacology Nanoparticles: Properties and Applications in Cancer Immunotherapy
Current Pharmaceutical Design Novel Agents Aiming at Specific Molecular Targets Increase Chemosensitivity and Overcome Chemoresistance in Hematopoietic Malignancies
Current Pharmaceutical Design Luminescent Silica Nanoparticles for Cancer Diagnosis
Current Medicinal Chemistry